Editorial
Editorial: Transient Ischemic Attacks and Aspirin, Stroke and Death; Negative Studies and Type II Error OF ALL SCIENTIFIC RESEARCH, clinical studies with their large number of recognized and unrecognized variables demand the most sophisticated and rigorous hypothesis testing and experimental design. Because of the small numbers and special charcteristics of a single center, large prospective double-blind cooperative studies have become necessary. Unfortunately, when multiple centers and investigators with different patient populations are involved, the probability of defects in design increases. Not unexpectly, the cooperative studies concerning the effect of the antiplatelet aggregating agent acetylsalicylic acid (aspirin) on stroke and death in patients with transient ischemic attacks (TIA) are no exception. 12 Nevertheless, despite different weaknesses, past multiple center studies have always shown significant differences in favor of aspirin over placebo. 34 In this issue, two additional prospective double-blind controlled cooperative studies are reported. 5, 6 For the first time one of these, the Danish study, 5 did not conclude that aspirin was effective in reducing stroke and death. Although the French study 6 was primarily a study of stroke and not TIAs, it did demonstrate a significant decrease in recurrent stroke and myocardial infarction in those who were treated with either aspirin or the combination of aspirin and dipyridamole. Thus, the results are similar to those of the Canadian 3 and the United States 4 cooperative studies.
Does the failure of the Danish study to show any favorable affect of aspirin mean that the other studies are wrong? If not, does it mean that Danes are different from Frenchman, Canadians and Americans? If neither of these alternatives are true, should one assume that the Danes were studying a different population of patients? If we analyze these studies, certain charactersitics suggest that none of the previous possibilities need necessarily be true. First, because of the high likelihood of Type II error in the Danish study, one should not conclude that, because it does not show a difference, none exists. In addition, there are other reasons that this study might have different results from the other cooperative studies. First, a number of risk factors were identified by the investigators that might affect outcome. They concluded that, as the occurrence of these factors was not significantly different between the placebo and aspirin groups, randomization was successful. One could look at this in a different way. Diseases and risk factors listed in the paper thought to be unfavorable, as determined in a previous study in the same hospitals 7 or by the Hospital Frequency Study of TIA, 8 are summarized (table 1) . Withdrawal from the study before an end point was considered to be favorable as once withdrawn the patient was no longer at risk. Although it is true that for each factor there is no statistical difference between the groups, in 15 of the 17 the trend is in favor of placebo. Though these factors may not be completely independent as required for the binomial distribution, if each had an equal chance of falling into either treatment group, the probability of 15 or more falling into one group would be about one in 400. Although the binomial formula is not entirely appropriate, one must still assume that the odds are quite high that the results in each group are not primarily related to the therapy prescribed. Also, using the binomial formula for the French, American and Canadian studies, the favorable risk factors occur randomly.
Additional differences from other studies are noted in both the Danish and the French studies. For example, in the Danish trial 306 patients presented to the study but 99 were excluded before randomization. Of the 207 that were randomized, four were dropped after randomization because the diagnosis was not correct. This left 203 patients of which 101 received aspirin and 102 placebo. From this point on, the authors analyzed all events on the basis of these numbers. Yet a substantial percentage of patients in each group discontinued the trial before an end point occurred and, therefore, were no longer at risk. This resulted in a very small number of patients remaining in the study (77 in the aspirin and 71 in the placebo group). Furthermore, half of the patients did not have platelet aggregation studies at six months and, of those who did, 10% who were assigned to the aspirin group yielded no aspirin effect in their blood samples. High withdrawal rates were also present in some of the other studies but in those with large numbers this was less critical. In the Danish study, only 67% of those taking aspirin had TIAs as compared to 76% of those taking placebo. All of these observations are confounding, indicating an unusual selection factor and an unusual drop out.
Both the Danish and French studies are interesting as they do not show any sex subgroup differences. The Canadian Study 3 noted that the favorable response to aspirin in men was significantly different than in females and a review of the American Study 4 and the Cooperative Hospital Frequency Study of TIA 8 supported the Canadian observation. In each of these studies women had fewer strokes and lower mortality than men regardless of treatment. 15 Data from Hospital Frequency Studies suggest that this might be primarily limited to older age men and one possibility was that older men had a greater loss of prostacyclin function so that the system was unbalanced. Another possibility is that because of the small number of events in females, larger numbers would need to be entered to reach statistical significance and if the evolution of the disease process is low it might take much longer than the average two to three years of follow-up performed in most cooperative studies for the effect to become apparent. The possibility exists that the lack of sex difference in the French study could be because 84% of the patients entering already had a more serious event, stroke, and that the time factor would be much less of a contributor. Of course, the Danish Study did not show any overall difference and it is not surprising that subgroups also did not show a difference.
Regardless of these problems, the Danish Study should be published and be available for reference because of the paucity of cooperative prospective studies. This critique is not intended to single it out as having more defects than other studies (which is not true), but to identify the differences so that they can be considered in analyses or as a base for planning future studies.
The most serious potential problem with the Danish Study is that, as many outstanding clinicians are not well based in statistical techniques, they might conclude after reading this paper that because no differences were noted between those treated with aspirin and placebo that the study indicates that aspirin is not effective. A number of excellent reviews in texts and journals have pointed out the high likelihood of Type II error (concluding that no real difference exists when it does) due to the small number of patients in many clinical studies. [9] [10] [11] [12] [13] [14] The aim of any randomized controlled trial is to estimate the real response rate for a treatment and to compare this to an estimate of the real rate for a control. Differences commonly are accepted as real when a small likelihood exists that they occur by chance. Each investigator must determine what risk will be taken before the study begins. Commonly, one accepts one chance in twenty (alpha equal to 0.05) or one in a hundred (alpha equal to 0.01). These are the probabilities of a Type I error (concluding differences are real when actually they are by chance). On the other hand if no statistically significant differences occur, do we assume that no real differences exist? If we do and there really is a difference, a Type II error has been made. To decrease the magnitude of a Type II error, before any study is initiated investigators must estimate the true response rates and what changes in these would be of practical importance at a clinical level. Once this has been done, they then must determine the acceptable level of a Type I error, and then estimate the power (1 -Type II error) of the trial to detect differences with reasonable confidence. For instance, using the Danish study as an example, it was assumed from previous studies that 20% of untreated patients would have a disabling stroke or die. If we accept that a onefourth reduction to 15% would be of practical clinical importance and we would like to accept a probability of less than 0.05 of making a Type I error, then we are in a position to estimate how many patients would be required in each group to detect this difference if it truly exists. For instance, if we wanted the power of the test to be 0.90 or a 90% chance of seeing a difference if it actually existed, we could then calculate how many patients would be required in each group. For this example, if we expect to have 90% chance of seeing a difference of 20% to 15% with an alpha level of 0.05, then 2,580 patients or 1,290 in each treatment group for a two-tailed test, would be required; or for a one-tailed test a total of 2,132 or 1,066 in each group. 13 Even a 50-50 chance of seeing the difference (power 0.5) would require a total of 1,042 for a two-tailed test or 776 for a one-tailed test. Similarly, to see a one-half reduction from 20% to 10% would require 610, 510, 270 or 210 total patients. Even if there had been no withdrawals in the Danish Study, 203 patients would not have been expected to show a difference if one existed. Therefore, one cannot conclude from this study that as no statistically significant difference was seen that, indeed, no real difference exists. To draw these conclusions, the study would have required somewhere between three to ten times the number entered. Fortunately, the authors do not draw these conclusions but the unsophisticated reader might. Indeed the authors point out that, even though a small difference in favor of placebo was observed, because of the very small numbers in the study, this observation is quite consistent with there being a true benefit of aspirin of as much as 50% reduction in events. This study should not be ignored as the previous prospective studies also have their defects. Regardless, if one assumes the Danish study is comparable to the American and Canadian studies and we combine all aspirin treated groups and all placebo groups, the statistical tests accepted by each study would still show a difference in favor of aspirin at much less than a 0.05 level.
In conclusion, two additional prospective doubleblind studies have been added to the literature. One gives additional support to previous studies. The second shows no statistical differences which would be expected even if a difference exists, because of the small number of patients entered. These studies have defined their population well, making it easy to recognize chance bias and, therefore, are available for reference and for future analysis. 
